Evidence map›Paper›PMID 42006153›Full record

ArticleThe journal of allergy and clinical immunology. Global2026

Immunologic desensitization to nilotinib in a patient with chronic myeloid leukemia with hypersensitivity and complex comorbidities.

Triaji Suryo Condro Widagdo, Deasy Fetarayani, Wita Kartika Nurani, Ari Baskoro, Gatot Soegiarto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Triaji Suryo Condro WidagdoFaculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Deasy FetarayaniDepartment of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Wita Kartika NuraniDepartment of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Ari BaskoroDepartment of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Gatot SoegiartoDepartment of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desensitization to nilotinib offers a viable solution for patients with chronic myeloid leukemia who are experiencing hypersensitivity, thus enabling continuation of targeted therapy. This approach supports molecular remission even in the presence of complex metabolic and neurologic comorbidities.

Indexed as

Chronic myeloid leukemiadesensitizationdrug hypersensitivitynilotinib

Identifiers

PMID42006153
PMCPMC13084656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.